Completed PHASE3 INTERVENTIONAL 1-arm NCT00556140

The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression (Abilify)

The Combination of Aripiprazole and Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants in the Acute Treatment of Psychotic Major Depression: Efficacy and Tolerability

Sponsor: Bristol-Myers Squibb

Conditions Psychotic Depression

Interventions Aripiprazole

Updated 8 times since 2017 Last updated: Jul 11, 2012 Started: Jun 30, 2003 Primary completion: Jan 31, 2008 Completion: Jan 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Psychotic Depression and is currently completed. Bristol-Myers Squibb leads this study, which shows 8 recorded versions since 2003 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE3
Dec 2021 — Dec 2022 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jan 2021 — Dec 2021 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jun 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb
Massachusetts General Hospital

Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States